A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo

Por Zhao, Lijie, Han, Xin, Lu, Jianfeng, McEachern, Donna, Wang, Shaomeng
Publicado no Neoplasia (2020)

Reactivation of p53 by MDM2 inhibitor MI-77301 for the treatment of endocrine-resistant breast cancer

Por Lu, Jianfeng, McEachern, Donna, Li, Shunqiang, Ellis, Matthew J., Wang, Shaomeng
Publicado no Mol Cancer Ther (2016)

LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling

Por Bai, Longchuan, McEachern, Donna, Yang, Chao-Yie, Lu, Jianfeng, Sun, Haiying, Wang, Shaomeng
Publicado em 2012

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo

Por Bai, Longchuan, Chen, Jianfang, McEachern, Donna, Liu, Liu, Zhou, Haibin, Aguilar, Angelo, Wang, Shaomeng
Publicado em 2014

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia in Vitro and in Vivo

Por Hoffman-Luca, C. Gianna, Ziazadeh, Daniel, McEachern, Donna, Zhao, Yujun, Sun, Wei, Debussche, Laurent, Wang, Shaomeng
Publicado no Clin Cancer Res (2015)

Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles

Por Aguilar, Angelo, Sun, Wei, Liu, Liu, Lu, Jianfeng, McEachern, Donna, Bernard, Denzil, Deschamps, Jeffrey R., Wang, Shaomeng
Publicado no J Med Chem (2014)

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

Por Hoffman-Luca, C. Gianna, Yang, Chao-Yie, Lu, Jianfeng, Ziazadeh, Daniel, McEachern, Donna, Debussche, Laurent, Wang, Shaomeng
Publicado no PLoS One (2015)

A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor

Por Aguilar, Angelo, Zhou, Haibin, Chen, Jianfang, Liu, Liu, Bai, Longchuan, McEachern, Donna, Yang, Chao-Yie, Meagher, Jennifer, Stuckey, Jeanne, Wang, Shaomeng
Publicado em 2013

Discovery of MD-224 as a First-in-Class, Highly Potent and Efficacious PROTAC MDM2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Por Li, Yangbing, Yang, Jiuling, Aguilar, Angelo, McEachern, Donna, Przybranowski, Sally, Liu, Liu, Yang, Chao-Yie, Wang, Mi, Han, Xin, Wang, Shaomeng
Publicado no J Med Chem (2018)

Structure-Based Discovery of BM-957 as a Potent Small-Molecule Inhibitor of Bcl-2 and Bcl-xL Capable of Achieving Complete Tumor Regression

Por Chen, Jianfang, Zhou, Haibin, Aguilar, Angelo, Liu, Liu, Bai, Longchuan, McEachern, Donna, Yang, Chao-Yie, Meagher, Jennifer L., Stuckey, Jeanne A., Wang, Shaomeng
Publicado em 2012

Structure-based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in vivo Antitumor Activity

Por Zhou, Haibin, Aguilar, Angelo, Chen, Jianfang, Bai, Longchuan, Liu, Liu, Meagher, Jennifer L., Yang, Chao-Yie, McEachern, Donna, Cong, Xin, Stuckey, Jeanne A., Wang, Shaomeng
Publicado em 2012

Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases

Por Yang, Jie, McEachern, Donna, Li, Wenyan, Davis, Mary A., Li, Hua, Morgan, Meredith A., Bai, Longchuan, Sebolt, Jonathan T., Sun, Haiying, Lawrence, Theodore S., Wang, Shaomeng, Sun, Yi
Publicado em 2011

Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity

Por Sun, Haiying, Liu, Liu, Lu, Jianfeng, Bai, Longchuan, Li, Xiaoqin, Nikolovska-Coleska, Zaneta, McEachern, Donna, Yang, Chao-Yie, Qiu, Su, Yi, Han, Sun, Duxin, Wang, Shaomeng
Publicado em 2011

A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

Por Zhao, Yujun, Yu, Shanghai, Sun, Wei, Liu, Liu, Lu, Jianfeng, McEachern, Donna, Shargary, Sanjeev, Bernard, Denzil, Li, Xiaoqin, Zhao, Ting, Zou, Peng, Sun, Duxin, Wang, Shaomeng
Publicado em 2013

Potent and Orally Active Small-Molecule Inhibitors of the MDM2-p53 Interaction

Por Yu, Shanghai, Qin, Dongguang, Shangary, Sanjeev, Chen, Jianyong, Wang, Guoping, Ding, Ke, McEachern, Donna, Qiu, Su, Nikolovska-Coleska, Zaneta, Miller, Rebecca, Kang, Sanmao, Yang, Dajun, Wang, Shaomeng
Publicado em 2009

A Potent Bivalent Smac Mimetic (SM-1200) Achieving Rapid, Complete and Durable Tumor Regression in Mice

Por Sheng, Rong, Sun, Haiying, Liu, Liu, Lu, Jianfeng, McEachern, Donna, Wang, Guanfeng, Wen, Jianfeng, Min, Ping, Du, Zhenyun, Lu, Huirong, Kang, Sanmao, Guo, Ming, Yang, Dajun, Wang, Shaomeng
Publicado em 2013

SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP

Por Lu, Jianfeng, Bai, Longchuan, Sun, Haiying, Nikolovska-Coleska, Zaneta, McEachern, Donna, Qiu, Su, Miller, Rebecca S., Yi, Han, Shangary, Sanjeev, Sun, Yi, Meagher, Jennifer L., Stuckey, Jeanne A., Wang, Shaomeng
Publicado em 2008

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Por Shangary, Sanjeev, Ding, Ke, Qiu, Su, Nikolovska-Coleska, Zaneta, Bauer, Joshua A., Liu, Meilan, Wang, Guoping, Lu, Yipin, McEachern, Donna, Bernard, Denzil, Bradford, Carol R., Carey, Thomas E., Wang, Shaomeng
Publicado em 2008

Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors

Por Zhao, Yujun, Liu, Liu, Sun, Wei, Lu, Jianfeng, McEachern, Donna, Xiaoqin, Li, Yu, Shanghai, Bernard, Denzil, Ochsenbein, Philippe, Ferey, Vincent, Carry, Jean-Christophe, Deschamps, Jeffrey R., Sun, Duxin, Wang, Shaomeng
Publicado em 2013

Therapeutic potential and molecular mechanism of a novel, potent, non-peptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment

Por Lu, Jianfeng, McEachern, Donna, Sun, Haiying, Bai, Longchuan, Peng, Yuefeng, Qiu, Su, Miller, Rebecca, Liao, Jinhui, Yi, Han, Liu, Meilan, Bellail, Anita, Hao, Chunhai, Sun, Shi-Yong, Ting, Adrian T., Wang, Shaomeng
Publicado em 2011